The Indian Pharma Market (IPM) is valued at Rs 6331 crores in September 2013 and has grown at -1.80 per cent.
The month also saw the launch of Lipaglyn (Saroglitazar) by Zydus in India. Amongst the top 10, Sun Pharma has seen a growth of 16 per cent followed by Zydus at 3.1 per cent and Lupin at three per cent. 29 corporates have crossed the growth of IPM for the month of September 2013 amongst the top 50 corporates.
Amongst the top 50 corporates, Corona Remedies has seen the highest growth of 58.4 per cent followed by Biocon at 40.6 per cent and Eris at 24.7 per cent.
Amongst the top 50 in MNCs Allergan grew the highest at 19.1 per cent, followed by Astra Zeneca at 8.5 per cent and MSD at 2.3 per cent. ohnson & Johnson and Merck were better than IPM growths.
Amongst the 11-20 ranked companies, Glenmark shows a high growth at 23.7 per cent followed by USV at 18.2 per cent and Intas at 14 per cent. Amongst upcoming corporates, Corona Remedies has seen a growth of 58.4 per cent, Eris at 24.7 per cent and Akumentis at 20.6 per cent.
 |
Dr Reddy’s Laboratories has crossed the Rs 1600-crores mark, UCB gets to Rs 150 crores in the IPM. Corona on MAT Basis have entered the top 50 in IPM.
Amongst the top 50 in MNCs, Allergan grew the highest at 19.1 per cent, followed by Astra Zeneca at 8.5 per cent and MSD at 2.3 per cent. Johnson & Johnson and Merck were better than IPM growths.
The DPCO 2013 containing molecules market degrew by -14.7 per cent whereas the non-DPCO market grew by a meagre 0.4 per cent resulting in an overall growth of -1.8 per cent for September 2013.
 |
The DPCO 2013 portfolio for GSK degrew at 25.4 per cent and Ranbaxy degrew by 7.7, whereas Sun Pharma had the least impact with its DPCO 2013 portfolio degrowing at 6.4 per cent. The market has witnessed a negative growths in the units as well in both the categories.
From a therapy perspective, 11 therapies outgrew IPM growth. The anti-infective market has a degrowth of -22.5 per cent whereas the respiratory market is at -8.2 per cent growth. The anti-diabetic market grew at 11.90 per cent and cardiac at 9.30 per cent in chronic business. Stomatologicals grew by 10 per cent, whereas derma market was at 9.6 per cent. Bonus in the anti-infective segment degrew by -16.7 per cent, whereas in respiratory market it was -13.8 per cent. At the regional level, 15 regions have outgrown the IPM growth. Karnataka grew highest at 6.4 per cent whereas UP East registered low growth in August 2013. The biggest region Tamil Nadu degrew at -2.1 per cent and 13 regions have had negative growths in August 13.
The biggest molecule Amoxycillin + Clavulanic degrew by 10 per cent, whereas Cefixime degrew at 28.9 per cent. Paracetamol degrew at 25.8 per cent and Azithromycin at 23.2 per cent. Glimepiride + Metformin grew at 42.6 per cent, Telmisartan grew by 21 per cent and Rosuvastain by 23.8 per cent.
About PharmaTrac
PharmaTrac is a the secondary sales data audit conducted by AIOCD Pharmasofttech AWACS, a pharmaceutical market research company formed by All Indian Origin Chemists & Distributors (AIOCD ) in a joint venture with Trikaal Mediinfotech. AWACS (Advanced Working, Action & Correction System) reflects the underlying philosophy behind AIOCD AWACS’ research tools to reduce time to information by 50 per cent or more and to significantly improve on accuracy of information.
Terminologies used
MAT – Moving Annual Total
MTH – Month
Val (Cr) – Value in Crores
MS per cent – Market Share in Percentage
GR per cent – Growth in percentage.
For more information, visit http://www.aiocd.net
- Advertisement -
